GGrantIndex
← Leaderboards

Xin-Liang Ma

Thomas Jefferson University

$9,519,870
Attributed
$10,307,328
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $788.4K · FY200624
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$10,307,328 · 4

By mechanism

R01$9,919,412 · 3
R56$387,916 · 1

Top collaborators

Most similar at Thomas Jefferson University

Same institution · by research overlap

Others in their field

Top investigators on “Signal Transduction

Research focus

Signal TransductionMyocardial IschemiaHeartMolecularCardiac MyocytesNovel TherapeuticsIn VitroPlayReperfusion TherapyReceptorMorbidity - Disease RateDiabeticCessation Of LifeDiabetic PatientDiabetes MellitusPathologicCardiovascular SystemAttenuatedMediatingCardiacAdiponectinCause Of DeathCellsBase

Grant awards (28)

Targeting Adiponectin for Cardioprotection in the Ischemic Heart$390,229
R01 · FY2024 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$390,229
R01 · FY2023 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2023 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$396,101
R01 · FY2022 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2022 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$398,357
R01 · FY2021 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2021 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2020 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$389,999
R01 · FY2019 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$390,001
R01 · FY2018 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$396,739
R01 · FY2017 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2017 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$397,260
R01 · FY2016 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2016 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$390,000
R01 · FY2015 · HL · contact PI
Cav-3 in Diabetic Myocardial Injury Following Ischemia/Reperfusion$387,916
R56 · FY2014 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$365,211
R01 · FY2013 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$383,625
R01 · FY2012 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$387,375
R01 · FY2011 · HL · contact PI
Targeting Adiponectin for Cardioprotection in the Ischemic Heart$386,667
R01 · FY2010 · HL · contact PI
Peroxynitrite in Cardiac Ischemia/Reperfusion$338,636
R01 · FY2010 · HL · contact PI
Peroxynitrite in Cardiac Ischemia/Reperfusion$338,636
R01 · FY2009 · HL · contact PI
Peroxynitrite in Cardiac Ischemia/Reperfusion$338,636
R01 · FY2008 · HL · contact PI
Peroxynitrite in Cardiac Ischemia/Reperfusion$338,636
R01 · FY2007 · HL · contact PI
Peroxynitrite in Cardiac Ischemia/Reperfusion$349,313
R01 · FY2006 · HL · contact PI
Peroxynitrite in Cardiac Ischemia/Reperfusion Injury$266,200
R01 · FY2003 · HL
Peroxynitrite in Cardiac Ischemia/Reperfusion Injury$273,610
R01 · FY2002 · HL
Peroxynitrite in Cardiac Ischemia/Reperfusion Injury$273,952
R01 · FY2001 · HL